VINC | tickerfilter.com

Fundamental analysis

18%

Profitability 0%

Dept financing 47%

Liquidity 50%

Performance 20%

Company vs Stock growth

N/A

0.339 0.567

0.227 66.94%

+ Add row to compare

Performance

5 Days

-10.26%

1 Month

-34.57%

3 Months

185.64%

6 Months

35.75%

1 Year

-48.77%

2 Year

-38.30%

Key data

Stock price

$0.54

P/E Ratio

0.00

DAY RANGE

$0.51 - $0.60

EPS

-$4.86

52 WEEK RANGE

$0.10 - $2.00

52 WEEK CHANGE

-$45.70

MARKET CAP

8.818 M

YIELD

N/A

SHARES OUTSTANDING

29.672 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

01-28-2025

NEXT EARNINGS DATE

04-15-2025

BETA

0.80

PUBLIC FLOAT

AVERAGE 10 VOLUME

$396,475

AVERAGE 30 VOLUME

$1,395,002

Company detail

CEO: Ahmed M. Hamdy
Region: US
Website: vincerx.com
Employees: 60
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Vincerx Pharma, Inc. researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors.

VINC - Vincerx Pharma, Inc.